Back to top
more

Eli Lilly (LLY)

(Delayed Data from NYSE)

$701.23 USD

701.23
8,213,998

+16.80 (2.45%)

Updated Aug 15, 2025 04:00 PM ET

After-Market: $701.31 +0.08 (0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 25% (61 out of 246)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Merck (MRK) to Supply Coronavirus Treatment to U.S. Government

by Zacks Equity Research

Merck (MRK) inks an agreement with the Government of United States for supplying MK-7110, being developed for treating patients with serious COVID-19, if approved.

Zacks Equity Research

Eli Lilly (LLY) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

Eli Lilly (LLY) closed at $165.48 in the latest trading session, marking a -0.74% move from the prior day.

Zacks Equity Research

Amgen (AMGN) Files for KRAS Inhibitor for Lung Cancer in Europe

by Zacks Equity Research

The regulatory filing for Amgen's (AMGN) sotorasib is based on data from a phase II study, which shows that sotorasib led to durable anticancer activity in advanced NSCLC patients with KRAS G12C mutation.

Zacks Equity Research

Here's Why Lilly (LLY) Has Outperformed the Industry This Year

by Zacks Equity Research

Lilly's (LLY) shares are up this year mainly due to rapid progress in its efforts to make antibodies to treat COVID-19.

Kinjel Shah headshot

Pharma Stock Roundup: FDA Emergency Nod to PFE/BNTX COVID-19 Vaccine, AZN to Buy ALXN

by Kinjel Shah

FDA grants approval for emergency use of Pfizer's (PFE) COVID-19 vaccine. AstraZeneca (AZN) offers to buy Alexion.

Zacks Equity Research

Eli Lilly (LLY) Gains But Lags Market: What You Should Know

by Zacks Equity Research

Eli Lilly (LLY) closed at $172.63 in the latest trading session, marking a +0.34% move from the prior day.

Zacks Equity Research

The Zacks Analyst Blog Highlights: Mastercard, Eli Lilly, Citigroup, Advanced Micro Devices and Square

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Mastercard, Eli Lilly, Citigroup, Advanced Micro Devices and Square

Zacks Equity Research

Amgen (AMGN) Submits NDA for KRAS Inhibitor for Lung Cancer

by Zacks Equity Research

The NDA filing for Amgen's (AMGN) sotorasib is based on data from a phase II study, which showed that sotorasib led to durable anticancer activity in advanced NSCLC patients with KRAS G12C mutation.

Sheraz Mian headshot

Top Analyst Reports for Mastercard, Eli Lilly & Citigroup

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including Mastercard (MA), Eli Lilly (LLY) and Citigroup (C).

Zacks Equity Research

Gilead (GILD) to Not Seek FDA Approval of RA Drug, Amends Deal

by Zacks Equity Research

Gilead (GILD) decides to not pursue FDA approval of filgotinib for the treatment of RA.

Zacks Equity Research

CytoDyn (CYDY) Completes Enrollment in Phase III COVID-19 Study

by Zacks Equity Research

CytoDyn (CYDY) completes full enrollment for its phase III registrational study of Vyrologix for the treatment of patients with severe-to-critical COVID-19.

Zacks Equity Research

Nektar (NKTR) Begins Dosing in NKTR-255 Study for Two Cancers

by Zacks Equity Research

Nektar (NKTR) doses the first patient in a phase I/II study on NKTR-255 in combination with Erbitux for treating head and neck squamous cell carcinoma or colorectal cancer. Shares up.

Zacks Equity Research

Lilly (LLY) to Acquire Prevail Therapeutics for Gene Therapies

by Zacks Equity Research

Lilly (LLY) inks a deal to acquire Prevail Therapeutics for an upfront payment of $880 million, which will add gene therapy programs to its pipeline.

Zacks Equity Research

Company News for Dec 16, 2020

by Zacks Equity Research

Companies In The News Are: CHWY, AAPL, LLY, BIDU.

Zacks Equity Research

Lilly (LLY) Stock Up on Raised 2020 View, Upbeat 2021 Guidance

by Zacks Equity Research

Eli Lilly's (LLY) stock up on Tuesday after it provides an upbeat financial guidance for the next year.

Zacks Equity Research

Eli Lilly (LLY) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

Eli Lilly (LLY) closed the most recent trading day at $160.04, moving -0.6% from the previous trading session.

Benjamin Rains headshot

3 Large-Cap Dividend Stocks to Buy and Hold Before 2021

by Benjamin Rains

Investors might not want to jump into stocks that are banking on a highly successful vaccine rollout. Therefore, we focused on 3 large-cap giants from completely different industries that pay a dividend and look poised to grow no matter what happens...

Kinjel Shah headshot

Pharma Stock Roundup: FDA Panel's Nod to PFE/BNTX Coronavirus Vaccine, Other Updates

by Kinjel Shah

An FDA panel recommends granting approval for emergency use of Pfizer's (PFE) COVID-19 vaccine. Glaxo (GSK)/Sanofi (SNY) COVID-19 vaccine plan delays.

Zacks Equity Research

Lilly's (LLY) Tirzepatide Meets Endpoints in Late-Stage Study

by Zacks Equity Research

Lilly's (LLY) tirzepatide demonstrates superiority in improving blood sugar levels and reducing body-weight compared to placebo in a phase III study evaluating in type 2 diabetes patients.

Zacks Equity Research

Company News for Dec 10, 2020

by Zacks Equity Research

Companies In The News Are: UNFI,CATM,FEYE,LLY

Zacks Equity Research

Eli Lilly (LLY) Soars: Stock Adds 5.8% in Session

by Zacks Equity Research

Eli Lilly (LLY) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

Zacks Equity Research

Roche (RHHBY), Moderna Ink Deal for Coronavirus Antibody Test

by Zacks Equity Research

Roche (RHHBY) partners with Moderna to allow the latter utilize its Elecsys Anti-SARS-CoV-2 S antibody test in the mRNA-1273 vaccine research studies.

Zacks Equity Research

Amgen's (AMGN) KRAS Inhibitor Gets Breakthrough Tag for NSCLC

by Zacks Equity Research

The FDA bestows a Breakthrough Therapy status on Amgen's (AMGN) KRAS inhibitor, sotorasib, for treating patients with advanced/metastatic non-small-cell lung cancer with KRAS G12C mutation.

Zacks Equity Research

Lilly (LLY)/UnitedHealth Launch COVID-19 Study on Bamlanivimab

by Zacks Equity Research

The pragmatic study by Lilly (LLY) and UnitedHealth Group (UNH) is set to evaluate bamlanivimab in high-risk symptomatic patients who test positive for COVID-19

Kinjel Shah headshot

Pharma Stock Roundup: Approval of PFE/BNTX Coronavirus Vaccine in UK, Other Updates

by Kinjel Shah

Pfizer (PFE) COVID-19 vaccine gets approval for emergency use in the United Kingdom while Roche's (RHHBY) Xolair gets FDA nod for new indication.